CuratioDL
Deep-learning-based Cancer Management Solutions
Company Overview
Snapshot
Founded in January 2021 by Rafi Heumann, Eran Gilboa, Prof. Jack Baniel, Prof. Yuval Shahar, Dr. Irit Arbel, and Prof. Kun-Hsing Yu, CuratioDL operates with 1–10 employees. The company has raised $817,000 across two funding rounds, with PipelBiz as an investor. CuratioDL holds an exclusive patented technology developed at Harvard University, which has been successfully tested on 10 types of cancer malignancies.
Business overview
CuratioDL specializes in cancer management solutions, leveraging deep-learning-powered pathology analysis to provide accurate diagnoses and prognoses. Its core technology facilitates personalized treatment plans for cancer patients by offering expert-level decision support, particularly for pathologists who may not be specialists in a specific field. The company operates within the Health Tech & Life Sciences sector, focusing on digital healthcare, and serves markets that include pharma companies, insurance companies, laboratories, and healthcare providers.
Strategic signal
CuratioDL's patented deep-learning technology, developed at Harvard University, has demonstrated high validation in diagnosing various cancer types and subtypes. This signals a significant advancement in precision medicine, offering the potential for more accurate and personalized cancer treatment strategies. For investors, this highlights the company's strong technological foundation and its potential to disrupt the cancer diagnostics market with a life-saving solution for early detection.
Log in to access full profile ›Company Intelligence Q&A
- What is CuratioDL's primary focus?
- CuratioDL focuses on providing cancer management solutions through deep-learning-powered pathology analysis, aiming to deliver accurate diagnoses and prognoses for personalized cancer treatment.
- When was CuratioDL founded?
- CuratioDL was founded in January 2021.
- What is the status of CuratioDL?
- CuratioDL is currently non-active and ceased to operate in February 2025.
- What technology does CuratioDL utilize?
- CuratioDL utilizes an exclusive patented deep-learning-based pre-processing segmentation technology developed at Harvard University, which has been successfully tested on 10 types of cancer malignancies.